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Recurrent skin abscesses are often associated with Panton-Valentine leukocidin-producing
strains of S. aureus (PVL-SA). Decolonization measures are required along with treatment
of active infections to prevent re-infection and spreading. Even though most PVL-SA
patients are treated as outpatients, there are few studies that assess the effectiveness of
outpatient topical decolonization in PVL-SA patients.
Methods
We assessed the results of topical decolonization of PVL-SA in a retrospective review of
patient files and personal interviews. Successful decolonization was defined as the absence
of any skin abscesses for at least 6 months after completion of the final decolonization treat-
ment. Clinical and demographic data was assessed. An intention-to-treat protocol was used.
Results
Our cohort consisted of 115 symptomatic patients, 66% from PVL-positive MSSA and 19%
from PVL-positive MRSA. The remaining 16% consisted of symptomatic patients with close
contact to PVL-SA positive index patients but without detection of PVL-SA. The majority of
patients were female (66%). The median age was 29.87% of the patients lived in multiple
person households. Our results showed a 48% reduction in symptomatic PVL-SA cases
after the first decolonization treatment. The results also showed that the decrease continued
with each repeated decolonization treatment and reached 89% following the 5th treatment.
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A built multivariable Cox proportional-hazards model showed that the absence of PVL-SA
detection (OR 2.0) and living in single person households (OR 2.4) were associated with an
independently increased chance of successful decolonization.
Conclusion
In our cohort, topical decolonization was a successful preventive measure for reducing the
risk of PVL-SA skin abscesses in the outpatient setting. Special attention should be given to
patients living in multiple person households because these settings could confer a risk that
decolonization will not be successful.
Introduction
Recurrent skin abscesses in patients who do not have a predisposing condition are often
associated with Panton-Valentine leukocidin-producing strains of S. aureus (PVL-SA) [1–3].
Although in North America PVL-SA is predominantly associated with community-acquired
MRSA related primarily to the clone USA 300 [3, 4], in Europe the vast majority of PVL-posi-
tive S. aureus (PVL-SA) strains are methicillin-susceptible (MSSA) [5]. The verification of
PVL-SA colonization or infection requires microbiological screening for S. aureus and addi-
tional PCR testing for the production of Panton-Valentine leukocidin by amplifying the
encoding genes LukS/LukF [1].
There can be a considerable delay in diagnosis despite its typical clinical presentation with
non-immunocompromised patients who suffer from recurrent skin abscesses. This results in
multiple episodes of skin infections and often leads to the transmission of pathogens to close
contacts [1, 2, 6, 7]. The diagnostic confirmation of a PVL-SA skin infection can be challenging
for several reasons. Although microbiological screening has a high sensitivity for monocloncal
PVL-positive MRSA, it is not clear how well nasal screening performs in cases of polyclonal
MSSA colonization [8–10]. Moreover, often many members of a family or individuals in the
same household can be affected. But the ping-pong-like transmission and retransmission
events of S. aureus can make PVL-SA colonization time-dependent [10, 11]. This makes it
difficult to eradicate PVL-SA colonization in all potential carriers.
After the primary treatment of PVL-SA-related infections, secondary prevention requires
topical decolonization [6, 12–14]. Despite the fact that many patients show relevant skin infec-
tions, most cases can be treated in an outpatient setting. This includes decolonization proce-
dures. However, there is a dearth of studies regarding outpatient decolonization and its specific
hurdles in the outpatient setting for patients with recurrent PVL-SA skin infections. Hence, in
this article we will focus on factors for the success of PVL-SA topical decolonization that are
relevant to the outpatient setting.
Methods
Our cohort consisted of patients with recurrent skin infections combined with the detection of
PVL-positive S. aureus (PVL-SA) as well as their close contacts who sometimes also displayed
symptoms. All cohort members were seen in our outpatient clinic between December 2010
and August 2017. Recurrence of an abscess was defined as more than one abscess that required
surgical drainage within a two-month period. Patients with a (predisposing) chronic skin con-
dition, e.g. Acne inversa or severe atopic dermatitis, were excluded from the present study. In
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aureus; PCR, polymerase chain reaction; PVL,
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clusters with more than one symptomatic and / or PVL-SA-positive patient, the topical decolo-
nization protocol was followed for all household members. In case of active PVL-SA skin
infections, patients received a rifampicin-based dual antibiotic regime combined with TMP/
SMX or as determined by antibiogram results. In addition, patients were advised to start a
decolonization treatment at home after the resolution of the infection. Decolonization
involved a 5-day standard decolonization protocol that included daily antiseptic washing of
the whole body and hair with a commercially available octenidin-based product, antiseptic
treatment of the oral cavity (octenidin-based), intranasal application of mupirocin, and
extended hygiene measures including the washing of clothes at more than 60˚C and disposing
of personal care products [2].
Success of the decolonization procedure was defined as a period of at least six months
without a skin abscess or other SSTI following completion of the decolonization treatment.
Decolonization was repeated in cases when skin abscesses recurred. The following variables
were systematically evaluated in interviews to assess the factors that reduced the success of
decolonization: age, gender, number of decolonization treatments, household size, number
of close contacts to the index case, abscess localization, and phenotype of PVL-SA (MRSA or
MSSA). A cluster was defined as individuals in the index patient’s immediate environment
(e.g. family or friends with frequent close physical contact) who were also colonized or infected
with PVL-SA. Household size was defined as the number of individuals living together in a
household with the index patient.
All patients were screened for PVL-SA in nares, throat and wounds, if applicable. Swabs
were cultivated on Columbia Agar with 5% sheep blood. Species identification and antimicro-
bial susceptibility testing were performed using a Vitek 2 system and applying EUCAST break-
points. The detection of PVL LukS/LukF was performed using PCR [15].
In order to assess parameters influencing the length of time needed for successful decoloni-
zation, we performed a univariate Kaplan-Meier analysis and a multivariable Cox regression
of all symptomatic patients, applying an intention-to-treat protocol. All analyses were per-
formed using SPSS (IBM SPSS statistics, Somer, NY, USA).
Ethics approval and consent to participate: The study was conducted in accordance with
the Declaration of Helsinki, national, and institutional standards. The study was approved by
the local Ethics Committee (Charite´, Berlin, Germany, EA2/190/17). The study is based on sec-
ondary data that was generated for routine clinical care. Within this scope, written consent for
treatment purposes and secondary analysis was provided by each patient. Consent for minors
under age 18 was obtained from parents or guardians. The Ethics Committee waived the
requirement for additional consent for this study.
Results
Sixty seven index patients with PVL-SA-positive recurrent skin abscesses presented to our out-
patient clinics between December 2010 and August 2017. Altogether, they reported 128 close
contacts (accounting for n: 195). 48 of 128 contacts reported recurrent skin abscesses. Of the
remaining 80 asymptomatic contacts, 40 contacts participated in PVL-SA screening, revealing
an additional 21 PVL-SA positive cases. The remaining 40 asymptomatic contact patients were
not available for examination of PVL-SA (Fig 1).
Taken together, of 155 patients and contacts, PVL-SA was verified in 118 cases (76%). One
patient was colonized with both phenotypes, hence 27 MRSA (23%), 92 MSSA (78%) were
detected.
By the time of diagnosis (skin abscess due to PVL-SA), the patients’ medical histories
showed a median of 4 episodes of skin abscesses (IQR 2–10) and a median delay of 5 months
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between first episode and final diagnosis (IQR 1–14). We found it helpful to calculate the aver-
age number of abscesses per month as an estimator of the severity of the infection and the psy-
chological strain on patients. The result was a median of 1.0 (IQR 0.3–2.8). Common abscess
sites included extremities (50%), trunk (47%), and head or face (42%), without any specific dis-
tribution pattern. Few patients (4%) showed invasive infections, such as necrotizing fasciitis,
necrotizing pneumonia or bloodstream infection.
Based on the patients’ past medical histories, many reported that they had undergone multi-
ple antibiotic treatments and multiple episodes of surgical intervention before being diagnosed
with skin abscesses from PVL-SA. 38 (33%) patients reported hospital stays for the treatment
of their recurrent abscesses with a length of stay between 1 and 42 days (median 3 days).
Table 1 provides an overview of all assessed parameters.
Following an intention-to-treat protocol, we analyzed all 115 symptomatic patients for suc-
cessful topical decolonization. 77 (67%) received systemic antimicrobial treatment beforehand
without relevant reduction in infection incidence. The median follow-up time was 15 months
after the final decolonization treatment. After the first decolonization treatment, the number
of symptomatic patients was reduced by 48% (56 patients) (Fig 2). 13 patients were lost to fol-
low up (11%). Altogether, this amounted to a success rate of 89% after 5 decolonization
treatments.
The following parameters were considered in the Cox regression analysis: age, gender,
number of decolonization treatments, single vs. multiple person household and phenotype of
PVL-SA (MSSA/MRSA). Factors independently associated with a successful decolonization
were living in a single household (in contrast to a multiple person household) and undetected
PVL-SA in symptomatic patients (Table 2 and Fig 3).
Discussion
Skin and soft tissue infection caused by PVL-positive S. aureus are frequently associated with
recurrent episodes of infection, delayed diagnoses, and eventually an increased risk of trans-
mission often resulting in clusters of affected patients in close personal proximity [1–3, 6, 16].
Although these infections are often community-acquired, there is a lack of literature that ana-
lyzes the effectiveness of outpatient decolonization [17, 18].
Fig 1. Flow chart of all enrolled patients.
https://doi.org/10.1371/journal.pone.0231772.g001
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Table 1. Overview on the analyzed PVL-SA patients.
Parameter Total cohort (n = 155) Clinically symptomatic (n = 115) Clinically asymptomatic (n = 40)
Median (range) / % (number) Median (range) / % (number) Median (range) / % (number)
Age (years) 29 (0–75) 28 (0–65) 31 (0–75)
Male sex 44% (68) 43% (49) 48% (19)
Months before diagnosis not applicable 5 (0–158) not applicable
Number of abscesses before diagnosis not applicable 4 (1–100) -
Number of antimicrobial treatments before diagnosis 1 (0–15) 1 (1–15) 0 (0–3)
Number of surgical treatments before diagnosis not applicable 1 (1–13) -
Detected pathogen PVL-positive S. aureus MRSA 17% (27) 19% (22) 13% (5)
MSSA 59% (92) 66% (76) 40% (16)
Not detected 24% (37) 16% (18) 48% (19)
Successful decolonization Yes 88% (137) 89% (102) not applicable
Lost to follow up 8% (13) 11% (13) -
Number of decolonization treatments 1 (1–5) 1 (1–5) 1 (1–3)
Household size Single person 10% (15) 13% (15) -
Multiple persons 90% (140) 87% (100) 100% (40)
Abscess Localization Extremities 37% (58) 50% (58) -
Trunk 35% (54) 47% (54) -
Head/Face 31% (48) 42% (48) -
Gluteal 22% (34) 30% (34) -
Axilla 13% (20) 17% (20) -
Genital 11% (17) 15% (17) -
Inguinal 5% (8) 7% (8) -
Invasive 3% (4) 4% (4) -
MRSA, methicillin-resistant S. aureus. MSSA, methicillin-susceptible S. aureus. PVL, Panton-Valentine leukodicin. Successful decolonization was defined as remaining
clinically asymptomatic for at least 6 months after final decolonization treatment.
https://doi.org/10.1371/journal.pone.0231772.t001
Fig 2. Kaplan-Meier curve of PVL-SA decolonization in 115 symptomatic patients. PVL-SA, Panton-Valentine
leukocidin-positive Staphylococcus aureus.
https://doi.org/10.1371/journal.pone.0231772.g002
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Pathogen transfer within households has been described repeatedly as the dominant trans-
mission route for community-acquired S. aureus in the past [7, 11, 19, 20]. Our data under-
scores this observation for PVL-SA, as we found that 69/88 (78%) contacts screened were also
clinically symptomatic and / or PVL-positive (Fig 1). The clinical relevance of household con-
tact is further emphasized by our observation that living in a multiple person household was a
relevant risk factor for requiring repeated decolonization as compared to living alone.
Knox et al. stated that the degree of physical contact among household members and the
amount of time spent at home determine the risk of transmission [11]. This could result in
epidemic S. aureus clones ‘ping-ponging’ between family members [19–22]. These observa-
tions support the need for the simultaneous decolonization of close physical contacts, at least
in cases where patients remain PVL-SA colonized despite decolonization treatment.
Table 2. Multivariable Cox regression analysis of parameters associated with successful decolonization.




MRSA 0.615 0.873 0.516 1.479
Undetected 0.012 2.030 1.170 3.523
Single household 0.006 2.372 1.285 4.381
PVL, pantone-valentine leukocidine. MSSA, Methicillin-susceptible S. aureus. MRSA, methicillin-resistant S. aureus.
OR, odds ratio.
https://doi.org/10.1371/journal.pone.0231772.t002
Fig 3. Multivariable Cox regression curve of PVL-SA decolonization in 115 symptomatic patients. PVL-SA,
Panton-Valentine leukocidin-positive Staphylococcus aureus.
https://doi.org/10.1371/journal.pone.0231772.g003
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Our results show that symptomatic patients in which PVL-SA could not be detected have a
higher chance of successful decolonization. Hence, this observation could be an indication
that a low-level colonization with PVL-SA might facilitate the eradication process. Earlier stud-
ies of MRSA decolonization have shown that the success of eradication can be dependent on
the localization of the colonization [23–25]. In our cohort, testing for PVL-SA was not per-
formed separately, using different swabs for nose and throat.
In the present study many patients reported a past medical history typical of PVL-SA
patients–recurrent skin abscess that often required incision and drainage and reporting other
affected patients in their immediate environment. PVL-SA-positive patients are often symp-
tomatic for several months, before they are finally diagnosed and treated for PVL-SA [16, 26–
29]. Our results thus underscore earlier work that shows that a diagnosis can be challenging in
areas with low PVL-SA prevalence [6, 30].
The patients in our cohort were on average 29 years old, confirming earlier studies on
patients with community-onset PVL-SA-associated skin abscess [30, 31]. Whether there are
socio-cultural or medico-biological factors driving this observation is unclear.
Our study has several limitations. This is a retrospective study on PVL-SA patients from a
single institution. It represents the patient population from our area and mirrors the results of
our locally established treatment procedures. All patients with an active infection were treated
with an oral antimicrobial agent—at least once—parallel to topical treatment. This makes it
impossible to determine the effect of the antimicrobial therapy on the decolonization results.
However, considering the fact that 2/3 of our patients had received antibiotics without any
topical decolonization and continued to suffer from recurrent skin abscesses argues against a
major protective role of isolated antibiotic use in these patients. Patients in our cohort had a
mean total of four skin abscesses in the five months prior to topical decolonization; after suc-
cessful decolonization, all patients were asymptomatic for at least 6 months with a mean fol-
low-up of 15.6 months.
Conclusion
Our data shows that patients with skin abscesses associated with PVL-SA can be successfully
treated with decolonization as outpatients, but they often require multiple attempts at decolo-
nization. The delayed success of treatment of patients living in multiple person households
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